Woodmont Investment Counsel LLC Increases Stock Holdings in Harrow, Inc. $HROW

Woodmont Investment Counsel LLC increased its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 2.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 106,213 shares of the company’s stock after buying an additional 2,520 shares during the quarter. Woodmont Investment Counsel LLC owned 0.29% of Harrow worth $3,244,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HROW. Quarry LP acquired a new stake in Harrow during the 1st quarter worth about $32,000. State of Wyoming acquired a new stake in Harrow during the 1st quarter worth about $97,000. Strs Ohio acquired a new stake in Harrow during the 1st quarter worth about $149,000. SJS Investment Consulting Inc. lifted its position in Harrow by 97.6% during the 2nd quarter. SJS Investment Consulting Inc. now owns 6,073 shares of the company’s stock worth $185,000 after acquiring an additional 3,000 shares during the period. Finally, Maridea Wealth Management LLC acquired a new stake in Harrow during the 2nd quarter worth about $202,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Price Performance

HROW stock opened at $45.43 on Monday. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58. The business has a 50 day simple moving average of $39.56 and a 200-day simple moving average of $32.26. The firm has a market capitalization of $1.68 billion, a PE ratio of -181.72 and a beta of 0.27. Harrow, Inc. has a 1 year low of $20.85 and a 1 year high of $59.23.

Harrow (NASDAQ:HROW) last posted its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.23. The business had revenue of $63.74 million during the quarter, compared to analyst estimates of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HROW. Zacks Research cut Harrow from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 12th. BTIG Research reiterated a “buy” rating and set a $63.00 price objective on shares of Harrow in a research note on Wednesday, September 24th. Lake Street Capital lifted their price objective on Harrow from $42.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Cantor Fitzgerald assumed coverage on Harrow in a research note on Friday, July 11th. They set an “overweight” rating and a $76.00 price objective for the company. Finally, B. Riley reiterated a “buy” rating and set a $74.00 price objective (up previously from $70.00) on shares of Harrow in a research note on Wednesday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Harrow has an average rating of “Moderate Buy” and an average target price of $68.50.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.